These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38620134)

  • 1. Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.
    Xiang X; Dai Z; Luo B; Zhao N; Liu S; Sui J; Huang J; Zhou Y; Gu J; Zhang J; Yang T; Bao R; Luo Y
    J Med Chem; 2024 Apr; 67(8):6769-6792. PubMed ID: 38620134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a Novel Series of Imipridone Compounds as
    Huang J; Zhang J; Luo B; Qiao W; Qiu Z; Song R; Dai Z; Sui J; Xu X; Ruan S; Li C; Luo Y; Yang T
    J Med Chem; 2022 Jun; 65(11):7629-7655. PubMed ID: 35609303
    [No Abstract]   [Full Text] [Related]  

  • 3. Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.
    Liu S; Sui J; Luo B; Zhang J; Xiang X; Yang T; Luo Y; Liu J
    J Med Chem; 2024 Jul; 67(13):10622-10642. PubMed ID: 38905539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Han X; Song N; Saidahmatov A; Wang P; Wang Y; Hu X; Kan W; Zhu W; Gao L; Zeng M; Wang Y; Li C; Li J; Liu H; Zhou Y; Wang J
    J Med Chem; 2021 Oct; 64(19):14647-14663. PubMed ID: 34477384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel SIRT3 inhibitors targeting both NAD
    Yang X; Ge G; Wang H; Liu T; Pan D; Zhao X; Chen X; Wang J; Zhang J; Zhang K; Yao D
    Eur J Med Chem; 2024 Oct; 276():116689. PubMed ID: 39053191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the structure-activity relationship and antileukemic activity of diacylpyramide compounds as human ClpP agonists.
    Zhang R; Wang P; Wei B; Chen L; Song X; Pan Y; Li J; Gan J; Zhang T; Yang CG
    Eur J Med Chem; 2023 Oct; 258():115577. PubMed ID: 37352796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
    Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.
    Jiang Y; Xu J; Yue K; Huang C; Qin M; Chi D; Yu Q; Zhu Y; Hou X; Xu T; Li M; Chou CJ; Li X
    J Med Chem; 2022 Jan; 65(1):285-302. PubMed ID: 34942071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
    Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
    Nii T; Prabhu VV; Ruvolo V; Madhukar N; Zhao R; Mu H; Heese L; Nishida Y; Kojima K; Garnett MJ; McDermott U; Benes CH; Charter N; Deacon S; Elemento O; Allen JE; Oster W; Stogniew M; Ishizawa J; Andreeff M
    Leukemia; 2019 Dec; 33(12):2805-2816. PubMed ID: 31127149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
    Tang Y; Zheng Y; Hu X; Zhao H; Cui S
    J Med Chem; 2024 Apr; 67(8):6638-6657. PubMed ID: 38577724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a Potent and Selective FLT3 Inhibitor (
    Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
    J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical Modulation of Human Mitochondrial ClpP: Potential Application in Cancer Therapeutics.
    Wong KS; Houry WA
    ACS Chem Biol; 2019 Nov; 14(11):2349-2360. PubMed ID: 31241890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
    Wang J; Li T; Zhao T; Wu T; Liu C; Ding H; Li Z; Bian J
    Eur J Med Chem; 2019 Sep; 178():782-801. PubMed ID: 31238183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
    Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
    Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
    ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
    Hsu YC; Coumar MS; Wang WC; Shiao HY; Ke YY; Lin WH; Kuo CC; Chang CW; Kuo FM; Chen PY; Wang SY; Li AS; Chen CH; Kuo PC; Chen CP; Wu MH; Huang CL; Yen KJ; Chang YI; Hsu JT; Chen CT; Yeh TK; Song JS; Shih C; Hsieh HP
    Oncotarget; 2016 Dec; 7(52):86239-86256. PubMed ID: 27863392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities.
    Xiao D; Wang YJ; Hu XB; Kan WJ; Zhang Q; Jiang X; Zhou YB; Li J; Lu W
    Eur J Med Chem; 2019 Aug; 176():419-430. PubMed ID: 31125896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Clinical Activity of Amino-Alcohol Dimeric Naphthoquinones as Potential Therapeutics for Acute Myeloid Leukemia.
    Ferraris D; Lapidus R; Truong P; Bollino D; Carter-Cooper B; Lee M; Chang E; LaRossa-Garcia M; Dash S; Gartenhaus R; Choi EY; Kipe O; Lam V; Mason K; Palmer R; Williams E; Ambulos N; Kamangar F; Zhang Y; Kapadia B; Jing Y; Emadi A
    Anticancer Agents Med Chem; 2022; 22(2):239-253. PubMed ID: 34080968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.